Antibody-Drug Conjugates in Clinical Trials for Lymphoid Malignancies and Multiple Myeloma
Antibody-drug conjugates (ADC) represent a distinct family of chemoimmunotherapy agents. ADCs are composed of monoclonal antibodies conjugated to cytotoxic payloads via specialized chemical linkers. ADCs therefore combine the immune therapy with targeted chemotherapy. Due to the distinct biomarkers associated with lymphocytes and plasma cells, ADCs have emerged as a promising treatment option for lymphoid malignancies and multiple myeloma. Several ADCs have been approved for clinical applications: brentuximab vedotin, inotuzumab ozogamicin, moxetumomab pasudotox, and polatuzumab vedotin. More novel ADCs are under clinical development. In this article, we summarized the general principles for ADC design, and updated novel ADCs under various stages of clinical trials for lymphoid malignancies and multiple myeloma.
Yu, B., & Liu, D. (2019). Antibody-Drug Conjugates in Clinical Trials for Lymphoid Malignancies and Multiple Myeloma. Journal of Hematology & Oncology, 12 (1), 94. https://doi.org/10.1186/s13045-019-0786-6